OTC COMMAND

OTC Command ⚔️ OTC DD, charts, filings, catalysts & sentiment. No hype. No fluff. Smarter speculation. NFA.

[OTC COMMAND @OTCCOMMAND]

$ATWT still one of the cleaner OTC setups I’m watching. Park-Aid closed, new CEO in place, share count held steady in Q1, and chart looks interesting if .0027 support holds. Needs follow-through above .0034. NFA

[OTC COMMAND @OTCCOMMAND]

Quick $LBRG read: tight float, AI/manufacturing story, and KST curling after a long base. Still high-risk OTC with preferred structure + restructuring history. Watching .0058-.0062 and .007+ for confirmation. NFA

[OTC COMMAND @OTCCOMMAND]

$BLIS $EMBR $PWDY $ATWT

[OTC COMMAND @OTCCOMMAND]

People still talk about safemoon dam. Its been 5yrs since I spoke about safemoon.

[THE SafeMoonGuy @theeSafeMoonGuy]

#SafeMoon is officially down 99.9%

What is next for this token?

[OTC COMMAND @OTCCOMMAND]

@ApePlissken01 @BrandedLegacy $bleg This reinforces the key point: authoritative data from official filings with OTC Markets and the Utah SOS is the only source of truth. Timely updates are essential for investors to perform accurate analysis. 🔍

[OTC COMMAND @OTCCOMMAND]

@ApePlissken01 @BrandedLegacy $bleg The mathematical proof shows a valuation discrepancy (ΔMC=MC1​−MC2​) of over $1.05 million. This is not a rounding error; it's a fundamental uncertainty about the company's value. 📉

[OTC COMMAND @OTCCOMMAND]

@ApePlissken01 @BrandedLegacy $bleg Using the day's price of P=$0.0006, we can calculate two vastly different market capitalizations:

Based on the 2.71B share count: MC1​=$0.0006×2,710,000,000=$1,626,000

Based on the 953.16M share count: MC2​=$0.0006×953,160,000=$571,896

[OTC COMMAND @OTCCOMMAND]

@ApePlissken01 @BrandedLegacy $bleg This perfectly illustrates the critical difference between secondary data aggregators and a company's primary, authoritative filings. The financial implications of such a discrepancy are not trivial.

[OTC COMMAND @OTCCOMMAND]

@gnikmj @BrandedLegacy Great find! The Jul 29, 2025, effective date fits the LOI's 'within 2 weeks' timeline perfectly. This is the company with a patented PBI device (7x higher absorption in trials) & a team projecting $40M Rev. Your find confirms the pivot to the $2.48B Naloxone market is happening

[OTC COMMAND @OTCCOMMAND]

Think of it like pizza. We had a small pizza, and now we're cutting it into more slices ($BLEG dilution). But those new slices are how we bought a much, much bigger pizza with better toppings! Your smaller piece is now part of a giant, amazing pizza. 🍕🙂

[OTC COMMAND @OTCCOMMAND]

Imagine $BLEG was a messy toy box. Now, a new grown up came with a special LEGO set! We gave away some toy coupons to get it, but this LEGO set can build a whole city! Don't listen to the kids who are still playing with the old, broken toys. 🚀

[OTC COMMAND @OTCCOMMAND]

@sccsd8 A 'dilution trap' implies dilution for no reason. This is strategic D for a merger with patented tech and a $40M Rev proj. The new leadership even cut authorized shares from 1.5B to 900M to enhance shareholder value. Check the facts before you call names. $bleg

[OTC COMMAND @OTCCOMMAND]

To all the $BLEG haters out there asking if I have a PhD... 🎓 well, our new leadership does! And they're bringing some serious addiction therapeutics expertise (plus a $40M revenue vision). This ain't your grandpa's team. #BLEG #PhDpower

[OTC COMMAND @OTCCOMMAND]

@sccsd8 @Stock_Pop The math is simple: BLEG's old $14k Q Rev is gone. The new co has a $40M Rev proj in a market growing from $1.07B to $2.48B by 2032. $bleg The new leadership's move from diversified ventures (horses & diapers) to a focused biotech with a patented device is a complete re-pivot!

[OTC COMMAND @OTCCOMMAND]

@sccsd8 @Stock_Pop You're living in the past. The entire prior mgmt team resigned. The new team strategically reduced auth shares from 1.5B to 900M to enhance value. The dilution is for a deal, not for them. That's a fact-based pivot not enrichment.

[OTC COMMAND @OTCCOMMAND]

The dilution authorized billions of shares to acquire a company with a patented device & a team projecting $40M in revenue At a P/S of just 1 that's a $40M market cap. Comparing that value to a $0002 price is missing the point. Dilution is the cost of a transformative deal $BLEG

[OTC COMMAND @OTCCOMMAND]

@gnikmj @JohnZidar The dilutionauthorized billions ofshares to acquire a companywith a patented device and projecting $40M in revenueAt a P/S of just 1, that's a $40M market cap Comparing that potential value to a $.0002 price is missing the point.The dilution is the cost of a transformative deal.

[OTC COMMAND @OTCCOMMAND]

@gnikmj That intranasal atomizer tech you spotted? It's directly connected to $BLEG's big news. They're acquiring Bio Eval Group, who own the patents on those intranasal drug delivery devices (think naloxone!). Huge move for $BLEG into a key market. Details here: https://t.co/7vsXAPkfR2

[OTC COMMAND @OTCCOMMAND]

@trippsb17 Exactly! Share structure noise often distracts from the real potential. If the fundamentals and vision are strong, like with $BLEG's new leadership & merger, that's where the focus should be. Good for you for seeing past the FUD!🤗

[OTC COMMAND @OTCCOMMAND]

@sccsd8 @Mister_Patience @BrandedLegacy Wow, quite the imagination you've got there. I'm just here talking stocks, not performing... personal services. Get a grip. $BLEG

[OTC COMMAND @OTCCOMMAND]

The intrinsic value of $BLEG post-merger hinges on commercializing its patented intranasal drug delivery. If the $40M revenue target is met, a 2x P/S multiple (still modest for biotech) could elevate market cap to $80M, translating to a share price of ~$0.042.